{"id":15726,"date":"2021-01-29T12:18:28","date_gmt":"2021-01-29T11:18:28","guid":{"rendered":"https:\/\/www.izb-online.de\/?p=15726"},"modified":"2021-01-29T13:36:46","modified_gmt":"2021-01-29T12:36:46","slug":"catalym-develops-novel-antibody-for-immune-cancer-therapy-to-improve-treatment-of-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/catalym-develops-novel-antibody-for-immune-cancer-therapy-to-improve-treatment-of-advanced-solid-tumors\/","title":{"rendered":"CatalYm develops novel antibody for immune cancer therapy to improve treatment of advanced solid tumors"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

CatalYm develops novel antibody for immune cancer therapy to improve treatment of advanced solid tumors<\/strong><\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]<\/p>\n

CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced in January 2021 the start of clinical development of CTL-002, its proprietary GDF-15 neutralizing antibody designed to enhance effector T cell entry into the tumor microenvironment. The first patient was enrolled and treated safely in December 2020 in this first clinical trial with CTL-002, acronymed GDFATHER <\/strong>(GDF<\/strong>-15 A<\/strong>ntibody-mediaT<\/strong>ed E<\/strong>ffector cell R<\/strong>elocation, NCT04725474). The company is located in the Biotechnology Innovation and Start-up Center in Martinsried near Munich.<\/p>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]Januar 2021[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text el_class=”gco-magazine-copyright”]<\/p>\n

\n
\n
\n
<\/div>\n
\n
<\/div>\n
\n

You are currently viewing a placeholder content from YouTube<\/strong>. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.<\/p>\n

More Information<\/a> <\/div>\n

Unblock content<\/a> Accept required service and unblock content<\/a> <\/div><\/div><\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 CatalYm GmbH[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]CatalYm entwickelt neuartigen Antik\u00f6rper f\u00fcr die Immun-Krebstherapie[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]GDFATHER <\/strong>is an open-label, multicenter, Phase I clinical trial evaluating intravenous (IV) administration of CTL-002 as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor. The trial is recruiting patients with advanced-stage, solid tumors, who have relapsed or are refractory to previous anti-PD-1\/PD-L1 treatments. The trial is designed with two stages: Part A being a dose escalation study to MTD of CTL-002 in combination with a checkpoint inhibitor and part B expansion cohorts of dedicated GDF-15-dependent tumor indications that are checkpoint inhibitor relapsed\/refractory. The trial is approved by regulators in Spain, Switzerland and Germany and may enroll up to 149 patients into part A and B combined.<\/p>\n

\u201cOur research has shown GDF-15 to be a malicious, tumor-produced factor that blocks immune effector cells from entering the tumor, thus interfering with immune cell activation and the killing of tumor cells. Blocking GDF-15 with CTL-002 should make modern immunotherapies more effective and potentially provide a major leap forward for the group of GDF-15-mediated checkpoint-inhibitor relapsed\/refractory patients,\u201d said Prof. Dr. Eugen Leo, Chief Medical Officer of CatalYm. \u201cMoreover, we are delighted that regulators appreciated our efficient and tailored trial design that includes the immediate combination of CTL-002 with a checkpoint inhibitor allowing participating patients access to a promising, attractive antibody combination therapy from the very start of this clinical trial.\u201d<\/p>\n

Dr. Manfred R\u00fcdiger, CEO of CatalYm, concluded: \u201cWe are proud of having achieved this important milestone, during this challenging time, that has involved great contributions from our team and our advisors. We look forward to delivering potentially better treatment options for patients failing on current checkpoint blocker treatment regimes.\u201d[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote gco-magazine–quote-vertical-center” css=”.vc_custom_1611918614473{margin-bottom: 12px !important;}”][vc_column_inner][vc_column_text]<\/p>\n


\n\u00a9 CatalYm GmbH<\/span><\/div>\n
\n
\u201cBlocking GDF-15 with CTL-002 should make modern immunotherapies more effective and potentially provide a major leap forward for the group of GDF-15-mediated checkpoint-inhibitor relapsed\/refractory patients.\u201d<\/h6>\n

Prof. Dr. Eugen Leo, Chief Medical Officer CatalYm<\/p>\n<\/div>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]CTL-002
\n<\/strong>CTL-002 is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). High concentrations of GDF-15 in the serum and tumor-microenvironment help the tumor evade the immune system and are associated with resistance to current therapies.* CTL-002 addresses three of the tumor\u2019s immune suppressive mechanisms all involving the inhibitory effect of GDF-15 on the immunostimulatory LFA-1\/ICAM-1 interaction. By neutralizing GDF-15, CTL-002 is expected to enhance infiltration of immune cells into the tumor, improve priming of T cells by dendritic cells and improve tumor killing by T cells and NK cells.<\/p>\n

About Concept of the clinical trail
\n<\/strong>The GDFATHER <\/strong>trial (GDF<\/strong>-15 A<\/strong>ntibody-mediaT<\/strong>ed E<\/strong>ffector cell R<\/strong>elocation) is a Phase I, first-in-human, multicenter, two-part (part A: dose escalation and part B: cohort expansion) clinical trial of intravenous (IV) administration of CTL-002 as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients with advanced-stage, relapsed\/refractory solid tumors, that relapsed post or were refractory to a prior anti-PD-1\/PD-L1 therapy. The primary objectives of the study are to characterize the safety and tolerability of CTL-002 and to explore the preliminary anti-tumor activity of CTL-002 in the expansion cohorts. More information on trial can be found at https:\/\/clinicaltrials.gov<\/a>.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote gco-magazine–quote-vertical-center” css=”.vc_custom_1611918619513{margin-bottom: 12px !important;}”][vc_column_inner][vc_column_text]<\/p>\n


\n\u00a9 CatalYm GmbH<\/span><\/div>\n
\n
\u201cWe look forward to delivering potentially better treatment options for patients failing on current checkpoint blocker treatment regime.\u201d<\/h6>\n

Dr. Manfred R\u00fcdiger, CEO CatalYm<\/p>\n<\/div>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]CatalYm is a biopharmaceutical company developing novel cancer immunotherapies targeting Growth-and-Differentiation Factor 15 (GDF-15). Apart from its established role in cachexia, GDF-15 has been associated with immunosuppression in tissues and tumors and a rapidly growing body of literature supports the concept that GDF-15 is a major T cell repellent. CatalYm aims to neutralize GDF-15 to turn \u201ccold\u201d tumors \u201chot\u201d and thereby substantially improving the efficacy of established immunotherapy such as anti-PD1\/-PD-L1 checkpoint inhibitors. The company\u2019s lead product candidate CTL-002, a neutralizing GDF-15 antibody, is currently under clinical evaluation in a two-part, open-label, multicenter, Phase I clinical trial (GDFATHER trial).<\/p>\n

References:<\/strong> * Front. Immunol. 11:951. doi: 10.3389\/fimmu.2020.00951[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n